| アブストラクト | We studied the incidence of subsequent fractures in persons of 50+ years from 1990 to 2012 and the relative risk (RR) of subsequent fractures after an index femur/hip fracture, stratified per 5-year age band. Patients suffering a fracture have a high incidence of a subsequent fracture; the RR of subsequent fracture after a femur/hip fracture ranged from 2 to 7. INTRODUCTION: Recent information on the risk of subsequent fractures after a broad range of index fractures in the UK population is scarce. We therefore studied the rates of subsequent fractures of the femur/hip, humerus, radius/ulna, vertebrae, rib, or pelvis after fractures at one of these sites from 1990 to 2012 in 3,156,347 UK men and women aged 50 years or over. METHODS: We undertook a retrospective observational study using the UK Clinical Practice Research Datalink (CPRD). The incidence of subsequent fractures at a specific site was calculated by dividing the observed number of fractures by the number of person-years (py) at risk. The relative risk (RR) of subsequent fractures after a femur/hip fracture, by 5-year age band, was calculated by dividing the incidence of a specific subsequent fracture type by the incidence of first fractures at the same site in the same age group. RESULTS: The highest subsequent fracture incidence after a femur/hip fracture was for humerus fracture in men (59.5/10.000 py) and radius/ulna fracture in women (117.2/10.000 py). After an index fracture of the radius/ulna, humerus fracture in men (59.3/10.000 py) and femur/hip fracture in women (82.4 per 10.000 py) were most frequent. The RR of fractures after a femur/hip fracture ranged from 2 to 7 and were highest in men and younger age groups. CONCLUSION: Patients suffering a fracture have a high incidence of a subsequent fracture. Our findings demonstrate the importance of fracture prevention in patients with a history of a fracture by adequate medical diagnosis and treatment. |
|---|
| 投稿者 | van der Velde, R Y; Wyers, C E; Geusens, P P M M; van den Bergh, J P W; de Vries, F; Cooper, C; van de Staa, T P; Harvey, N C |
|---|
| 組織名 | Department of Internal Medicine, VieCuri Medical Centre, PO Box 1926, 5900 BX,;Venlo, The Netherlands.;Department of Internal Medicine, NUTRIM School for Nutrition, Toxicology and;Metabolism, Maastricht University Medical Centre (MUMC), PO Box 616, 6200 MD,;Maastricht, The Netherlands.;Department of Internal Medicine, Subdivision Rheumatology, CAPHRI, Maastricht;University Medical Centre (MUMC), PO Box 616, 6200 MD, Maastricht, The;Netherlands.;Biomedical Research Centre, Hasselt University, Agoralaan - gebouw D, 3590,;Diepenbeek, Belgium.;Department of Clinical Pharmacy & Toxicology, Maastricht University Medical;Centre+, Maastricht, The Netherlands.;Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for;Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.;MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.;cc@mrc.soton.ac.uk.;NIHR Southampton Biomedical Research Centre, University of Southampton and;University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton,;UK. cc@mrc.soton.ac.uk.;NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.;Health eResearch Centre, University of Manchester, Manchester, UK.;UK. |
|---|
